Trial Condition(s):

Prostate Cancer

Androcur Effects on Quality of Life

Bayer Identifier:

14166

ClinicalTrials.gov Identifier:

NCT00908674

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Androcur is an antiandrogenic drug, which blocks the action of male sex hormones. Androcur is used for treatment of advanced prostate cancer. This study investigates the effect of Androcur on quality of life of prostate cancer patients who are taking the drug for 12 months

Inclusion Criteria
- Histologically confirmed adenocarcinoma of the prostate
 - Inoperable prostate tumor or progradiated after surgery/ irradiation therapy
 - Locally advanced tumor or distant metastases is present
Exclusion Criteria
- Patient not fulfil the recruitment criteria
 - Liver disease; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumours (in carcinoma of the prostate only if these are not due to metastases); wasting diseases (with the exception of carcinoma of the prostate); depression; previous or existing thromboembolic processes; diabetes with vascular changes; sickle-cell anaemia.
 - As regards patients with prostatic carcinoma who have a history of thromboembolic processes and/or an existing sickle-cell anaemia, or diabetes with vascular changes, the risk:benefit ratio must be considered carefully in each individual case before the use of Androcur

Trial Summary

Enrollment Goal
245
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Androcur (Cyproterone Acetate, BAY94-8367)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Hungary

Status
Completed
 

Trial Design